Jones Financial Companies
DRMA icon

Jones Financial Companies’s Dermata Therapeutics DRMA Stock Holding History

Jones Financial Companies’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,200
Closed -$7.25K – 4264
2025
Q2 		$7.25K Hold
1,200
– – ﹤0.01% 2990
2025
Q1 		$14.2K Buy
+1,200
New +$14.8K ﹤0.01% 2559

Other funds holding DRMA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Jones Financial Companies's DRMA Position: Q3 2025 in Review

Jones Financial Companies sold out of Dermata Therapeutics (DRMA) in Q3 2025, closing a stake of 1,200 shares — an estimated $7.25K sold.

Jones Financial Companies first reported a position in DRMA in Q1 2025 and held it in 2 quarters. The position peaked at $14.2K in Q1 2025. 5 funds tracked by Wall St. Rank hold DRMA as of Q3 2025.

  • Jones Financial Companies reported no remaining Dermata Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jones Financial Companies sold 1,200 Dermata Therapeutics shares in Q3 2025, an estimated $7.25K.
  • Jones Financial Companies first reported a position in Dermata Therapeutics in Q1 2025 and held it in 2 quarters.
  • Jones Financial Companies's Dermata Therapeutics position peaked at $14.2K in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q3 2025.

Based on Jones Financial Companies's 13F filing for Q3 2025, filed 4 Nov 2025.